Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors
Purpose To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs). Patients and methods Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEG...
Gespeichert in:
| Veröffentlicht in: | Graefe's archive for clinical and experimental ophthalmology 2022-03, Vol.260 (3), p.1005-1014 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1014 |
|---|---|
| container_issue | 3 |
| container_start_page | 1005 |
| container_title | Graefe's archive for clinical and experimental ophthalmology |
| container_volume | 260 |
| creator | Moret, E. Ambresin, A. Gianniou, C. Bijon, J. Besse-Hayat, C. Bogiatzi, S. Hohl, D. Spertini, F. Mantel, I. |
| description | Purpose
To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs).
Patients and methods
Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept.
Results
Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence.
Conclusion
Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease. |
| doi_str_mv | 10.1007/s00417-021-05353-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8850288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2573437793</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-1837328c529a008d22dbc8f2336915b42e95d4e6e5869f11e23cdfe160657c493</originalsourceid><addsrcrecordid>eNp9kU1vEzEYhC1ERUPhD3BAK3HhYupvey9IqIKCVJULSL1ZjvfdxNXGDrY3KP8epykFeuDkwzwez3gQekXJO0qIPi-ECKoxYRQTySXH_AlaUMEl1oTdPEULoptkOLs5Rc9LuSWN55I-Q6dcSNZTLhZoe50iDpsNDMFV6IY8r7r1fgu5QCyhhl2o-y6D8zWkWLoCPsXB5X1XUxdiza4BTZ46F2vAO1f8PLncQRxSXcMUmrLK6Wddd2PzSLm8QCejmwq8vD_P0PdPH79dfMZXXy-_XHy4wl5oUTE1XHNmfMvpCDEDY8PSm5Fxrnoql4JBLwcBCqRR_UgpMO6HEagiSmoven6G3h99t_OytfNwCDvZbQ6bFt8mF-y_Sgxru0o7a4wkzJhm8PbeIKcfM5RqN6F4mCYXIc3FMqm54Fr3vKFvHqG3ac6x1bNMtY9WTKlDInakfE6lZBgfwlBiD4Pa46C2DWrvBrUH69d_13i48nvBBvAjUJoUV5D_vP0f2190da6t</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2629162669</pqid></control><display><type>article</type><title>Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors</title><source>MEDLINE</source><source>SpringerNature Complete Journals</source><creator>Moret, E. ; Ambresin, A. ; Gianniou, C. ; Bijon, J. ; Besse-Hayat, C. ; Bogiatzi, S. ; Hohl, D. ; Spertini, F. ; Mantel, I.</creator><creatorcontrib>Moret, E. ; Ambresin, A. ; Gianniou, C. ; Bijon, J. ; Besse-Hayat, C. ; Bogiatzi, S. ; Hohl, D. ; Spertini, F. ; Mantel, I.</creatorcontrib><description>Purpose
To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs).
Patients and methods
Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept.
Results
Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence.
Conclusion
Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease.</description><identifier>ISSN: 0721-832X</identifier><identifier>EISSN: 1435-702X</identifier><identifier>DOI: 10.1007/s00417-021-05353-3</identifier><identifier>PMID: 34529134</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Allergies ; Angiogenesis Inhibitors - adverse effects ; Bevacizumab ; Bevacizumab - adverse effects ; Drug Hypersensitivity - diagnosis ; Drug Hypersensitivity - drug therapy ; Drug Hypersensitivity - etiology ; Fever ; Growth factors ; Hematuria ; Humans ; Hypersensitivity (immediate) ; Intravitreal Injections ; Medical Ophthalmology ; Medicine ; Medicine & Public Health ; Monoclonal antibodies ; Ophthalmology ; Patients ; Proteinuria ; Purpura ; Ranibizumab - adverse effects ; Receptors, Vascular Endothelial Growth Factor ; Recombinant Fusion Proteins ; Reintroduction ; Retrospective Studies ; Side effects ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A</subject><ispartof>Graefe's archive for clinical and experimental ophthalmology, 2022-03, Vol.260 (3), p.1005-1014</ispartof><rights>The Author(s) 2021. corrected publication 2022</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021, corrected publication 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-1837328c529a008d22dbc8f2336915b42e95d4e6e5869f11e23cdfe160657c493</citedby><cites>FETCH-LOGICAL-c474t-1837328c529a008d22dbc8f2336915b42e95d4e6e5869f11e23cdfe160657c493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00417-021-05353-3$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00417-021-05353-3$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34529134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moret, E.</creatorcontrib><creatorcontrib>Ambresin, A.</creatorcontrib><creatorcontrib>Gianniou, C.</creatorcontrib><creatorcontrib>Bijon, J.</creatorcontrib><creatorcontrib>Besse-Hayat, C.</creatorcontrib><creatorcontrib>Bogiatzi, S.</creatorcontrib><creatorcontrib>Hohl, D.</creatorcontrib><creatorcontrib>Spertini, F.</creatorcontrib><creatorcontrib>Mantel, I.</creatorcontrib><title>Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors</title><title>Graefe's archive for clinical and experimental ophthalmology</title><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><description>Purpose
To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs).
Patients and methods
Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept.
Results
Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence.
Conclusion
Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease.</description><subject>Allergies</subject><subject>Angiogenesis Inhibitors - adverse effects</subject><subject>Bevacizumab</subject><subject>Bevacizumab - adverse effects</subject><subject>Drug Hypersensitivity - diagnosis</subject><subject>Drug Hypersensitivity - drug therapy</subject><subject>Drug Hypersensitivity - etiology</subject><subject>Fever</subject><subject>Growth factors</subject><subject>Hematuria</subject><subject>Humans</subject><subject>Hypersensitivity (immediate)</subject><subject>Intravitreal Injections</subject><subject>Medical Ophthalmology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Monoclonal antibodies</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Proteinuria</subject><subject>Purpura</subject><subject>Ranibizumab - adverse effects</subject><subject>Receptors, Vascular Endothelial Growth Factor</subject><subject>Recombinant Fusion Proteins</subject><subject>Reintroduction</subject><subject>Retrospective Studies</subject><subject>Side effects</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A</subject><issn>0721-832X</issn><issn>1435-702X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kU1vEzEYhC1ERUPhD3BAK3HhYupvey9IqIKCVJULSL1ZjvfdxNXGDrY3KP8epykFeuDkwzwez3gQekXJO0qIPi-ECKoxYRQTySXH_AlaUMEl1oTdPEULoptkOLs5Rc9LuSWN55I-Q6dcSNZTLhZoe50iDpsNDMFV6IY8r7r1fgu5QCyhhl2o-y6D8zWkWLoCPsXB5X1XUxdiza4BTZ46F2vAO1f8PLncQRxSXcMUmrLK6Wddd2PzSLm8QCejmwq8vD_P0PdPH79dfMZXXy-_XHy4wl5oUTE1XHNmfMvpCDEDY8PSm5Fxrnoql4JBLwcBCqRR_UgpMO6HEagiSmoven6G3h99t_OytfNwCDvZbQ6bFt8mF-y_Sgxru0o7a4wkzJhm8PbeIKcfM5RqN6F4mCYXIc3FMqm54Fr3vKFvHqG3ac6x1bNMtY9WTKlDInakfE6lZBgfwlBiD4Pa46C2DWrvBrUH69d_13i48nvBBvAjUJoUV5D_vP0f2190da6t</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Moret, E.</creator><creator>Ambresin, A.</creator><creator>Gianniou, C.</creator><creator>Bijon, J.</creator><creator>Besse-Hayat, C.</creator><creator>Bogiatzi, S.</creator><creator>Hohl, D.</creator><creator>Spertini, F.</creator><creator>Mantel, I.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220301</creationdate><title>Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors</title><author>Moret, E. ; Ambresin, A. ; Gianniou, C. ; Bijon, J. ; Besse-Hayat, C. ; Bogiatzi, S. ; Hohl, D. ; Spertini, F. ; Mantel, I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-1837328c529a008d22dbc8f2336915b42e95d4e6e5869f11e23cdfe160657c493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Allergies</topic><topic>Angiogenesis Inhibitors - adverse effects</topic><topic>Bevacizumab</topic><topic>Bevacizumab - adverse effects</topic><topic>Drug Hypersensitivity - diagnosis</topic><topic>Drug Hypersensitivity - drug therapy</topic><topic>Drug Hypersensitivity - etiology</topic><topic>Fever</topic><topic>Growth factors</topic><topic>Hematuria</topic><topic>Humans</topic><topic>Hypersensitivity (immediate)</topic><topic>Intravitreal Injections</topic><topic>Medical Ophthalmology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Monoclonal antibodies</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Proteinuria</topic><topic>Purpura</topic><topic>Ranibizumab - adverse effects</topic><topic>Receptors, Vascular Endothelial Growth Factor</topic><topic>Recombinant Fusion Proteins</topic><topic>Reintroduction</topic><topic>Retrospective Studies</topic><topic>Side effects</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moret, E.</creatorcontrib><creatorcontrib>Ambresin, A.</creatorcontrib><creatorcontrib>Gianniou, C.</creatorcontrib><creatorcontrib>Bijon, J.</creatorcontrib><creatorcontrib>Besse-Hayat, C.</creatorcontrib><creatorcontrib>Bogiatzi, S.</creatorcontrib><creatorcontrib>Hohl, D.</creatorcontrib><creatorcontrib>Spertini, F.</creatorcontrib><creatorcontrib>Mantel, I.</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moret, E.</au><au>Ambresin, A.</au><au>Gianniou, C.</au><au>Bijon, J.</au><au>Besse-Hayat, C.</au><au>Bogiatzi, S.</au><au>Hohl, D.</au><au>Spertini, F.</au><au>Mantel, I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors</atitle><jtitle>Graefe's archive for clinical and experimental ophthalmology</jtitle><stitle>Graefes Arch Clin Exp Ophthalmol</stitle><addtitle>Graefes Arch Clin Exp Ophthalmol</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>260</volume><issue>3</issue><spage>1005</spage><epage>1014</epage><pages>1005-1014</pages><issn>0721-832X</issn><eissn>1435-702X</eissn><abstract>Purpose
To describe a series of non-immediate drug hypersensitivity reactions after intravitreal anti-vascular endothelial growth factors (anti-VEGFs).
Patients and methods
Retrospective report of 6 patients with cutaneous non-immediate drug hypersensitivity reactions following intravitreal anti-VEGF injections, 4 after ranibizumab, 1 after bevacizumab and 1 after aflibercept.
Results
Clinical manifestations ranged from mild maculopapular rash, purpura to severe generalized erythroderma, with or without systemic involvement such as microscopic hematuria and proteinuria or fever. In two out of the six patients, reintroduction of either the same or an alternative anti-VEGF drug did induce a recurrence of the drug hypersensitivity reaction, while 4 patients showed no recurrence.
Conclusion
Cutaneous non-immediate drug hypersensitivity reactions secondary to intravitreal anti-VEGF may occur. Continuation of the same drug or switch to another anti-VEGF may either induce recurrence or be well supported by the patient. The decision of drug discontinuation should be guided by the severity of the disease.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34529134</pmid><doi>10.1007/s00417-021-05353-3</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0721-832X |
| ispartof | Graefe's archive for clinical and experimental ophthalmology, 2022-03, Vol.260 (3), p.1005-1014 |
| issn | 0721-832X 1435-702X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8850288 |
| source | MEDLINE; SpringerNature Complete Journals |
| subjects | Allergies Angiogenesis Inhibitors - adverse effects Bevacizumab Bevacizumab - adverse effects Drug Hypersensitivity - diagnosis Drug Hypersensitivity - drug therapy Drug Hypersensitivity - etiology Fever Growth factors Hematuria Humans Hypersensitivity (immediate) Intravitreal Injections Medical Ophthalmology Medicine Medicine & Public Health Monoclonal antibodies Ophthalmology Patients Proteinuria Purpura Ranibizumab - adverse effects Receptors, Vascular Endothelial Growth Factor Recombinant Fusion Proteins Reintroduction Retrospective Studies Side effects Vascular endothelial growth factor Vascular Endothelial Growth Factor A |
| title | Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A57%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-immediate%20drug%20hypersensitivity%20reactions%20secondary%20to%20intravitreal%20anti-vascular%20endothelial%20growth%20factors&rft.jtitle=Graefe's%20archive%20for%20clinical%20and%20experimental%20ophthalmology&rft.au=Moret,%20E.&rft.date=2022-03-01&rft.volume=260&rft.issue=3&rft.spage=1005&rft.epage=1014&rft.pages=1005-1014&rft.issn=0721-832X&rft.eissn=1435-702X&rft_id=info:doi/10.1007/s00417-021-05353-3&rft_dat=%3Cproquest_pubme%3E2573437793%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2629162669&rft_id=info:pmid/34529134&rfr_iscdi=true |